{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:52:02Z","timestamp":1779205922965,"version":"3.51.4"},"reference-count":29,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100002597","name":"Kyung Hee University","doi-asserted-by":"publisher","award":["KHU-20222246"],"award-info":[{"award-number":["KHU-20222246"]}],"id":[{"id":"10.13039\/501100002597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Low-density lipoprotein cholesterol (LDL-C)-lowering therapy is considerably important in preventing cardiovascular disease (CVD) among patients with diabetes. Studies comparing CVD, stroke, and mortality outcomes of low- or moderate-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy in patients with diabetes remain lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study compared the primary prevention effect of myocardial infarction (MI), stroke, and all-cause death between combination therapy of low- or moderate-intensity statins and ezetimibe and high-intensity statin monotherapy in patients with diabetes using the Korean National Health Insurance claims database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged \u226520 years with type 2 diabetes and dyslipidemia were enrolled. The combination therapy of low- or moderate-intensity statin and ezetimibe was compared with high-intensity statin monotherapy after a propensity score\u2013matched analysis. The incidence of composite outcomes consisting of MI, stroke, and all-cause death and each component were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In moderate-intensity statin therapy with ezetimibe combination therapy, LDL-C (74 \u00b1 37.9\u2005mg\/dL vs 80.8 \u00b1 38.8\u2005mg\/dL, P &amp;lt; .001) and the incidence of composite outcomes were lower (hazard ratio 0.85, 95% CI 0.74-0.98) than those in high-intensity statin monotherapy. Meanwhile, no significant difference was observed in the LDL-C levels and composite outcomes between low-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C\u2013lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad714","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T05:27:18Z","timestamp":1704259638000},"page":"1883-1890","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes"],"prefix":"10.1210","volume":"109","author":[{"given":"So Young","family":"Park","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital , Seoul 02447 ,","place":["Republic of Korea"]},{"name":"Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine , Seoul 02453 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7204-4913","authenticated-orcid":false,"given":"Ji Eun","family":"Jun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine , Seoul 02453 ,","place":["Republic of Korea"]},{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong , Seoul 05278 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-546X","authenticated-orcid":false,"given":"In-Kyung","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine , Seoul 02453 ,","place":["Republic of Korea"]},{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong , Seoul 05278 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Jeung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine , Seoul 02453 ,","place":["Republic of Korea"]},{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong , Seoul 05278 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yeon","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine , Seoul 02453 ,","place":["Republic of Korea"]},{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong , Seoul 05278 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-7874","authenticated-orcid":false,"given":"You-Cheol","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine , Seoul 02453 ,","place":["Republic of Korea"]},{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong , Seoul 05278 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"24","key":"2024102821415971000_dgad714-B1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u2014mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"2024102821415971000_dgad714-B2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.metabol.2014.08.010","article-title":"Diabetic dyslipidemia","volume":"63","author":"Wu","year":"2014","journal-title":"Metabolism"},{"issue":"1","key":"2024102821415971000_dgad714-B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","article-title":"Diabetes, cardiovascular disease and the microcirculation","volume":"17","author":"Strain","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"9435","key":"2024102821415971000_dgad714-B4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"2024102821415971000_dgad714-B5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"9753","key":"2024102821415971000_dgad714-B6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists C","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2024102821415971000_dgad714-B7","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American heart association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"2024102821415971000_dgad714-B8","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"2024102821415971000_dgad714-B9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"2024102821415971000_dgad714-B10","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc21-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes A","year":"2021","journal-title":"Diabetes Care"},{"issue":"25","key":"2024102821415971000_dgad714-B11","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/CIRCULATIONAHA.118.038629","article-title":"The new 2018 cholesterol guidelines","volume":"139","author":"Khera","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"2024102821415971000_dgad714-B12","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"10349","key":"2024102821415971000_dgad714-B13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"29","key":"2024102821415971000_dgad714-B14","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"issue":"24","key":"2024102821415971000_dgad714-B15","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024102821415971000_dgad714-B16","author":"Park"},{"issue":"3","key":"2024102821415971000_dgad714-B17","first-page":"354","article-title":"Ezetimibe (Zetia): a new type of lipid-lowering agent","volume":"16","author":"Patel","year":"2003","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"12","key":"2024102821415971000_dgad714-B18","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"issue":"6","key":"2024102821415971000_dgad714-B19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"2024102821415971000_dgad714-B20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.atherosclerosis.2014.10.105","article-title":"Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis","volume":"237","author":"Ambegaonkar","year":"2014","journal-title":"Atherosclerosis"},{"issue":"7","key":"2024102821415971000_dgad714-B21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/M13-2526","article-title":"Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review","volume":"160","author":"Gudzune","year":"2014","journal-title":"Ann Intern Med"},{"issue":"11","key":"2024102821415971000_dgad714-B22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","article-title":"Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial","volume":"44","author":"Lee","year":"2022","journal-title":"Eur Heart J"},{"issue":"25 Suppl 2","key":"2024102821415971000_dgad714-B23","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"2024102821415971000_dgad714-B24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"issue":"1","key":"2024102821415971000_dgad714-B25","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1038\/s41598-021-86090-9","article-title":"Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks","volume":"11","author":"Kao","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"2024102821415971000_dgad714-B26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2024102821415971000_dgad714-B27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10787-022-01053-4","article-title":"The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Arabi","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"5","key":"2024102821415971000_dgad714-B28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2024102821415971000_dgad714-B29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2015.05.064","article-title":"Ezetimibe and plaque regression: cholesterol lowering or pleiotropic effects?","volume":"66","author":"Crea","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad714\/55023885\/dgad714.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/7\/1883\/60177649\/dgad714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/7\/1883\/60177649\/dgad714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T21:42:12Z","timestamp":1730151732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/7\/1883\/7510780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,1,4]]},"published-print":{"date-parts":[[2024,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad714","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,1,4]]}}}